Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,006 matching trials from the live ClinicalTrials.gov search.

Filters: "hormone-sensitive" Clear all

Conditions: Type 1 Diabetes
Interventions: Acipimox, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cushing Disease, Pituitary Adenoma
Interventions: Fluoro-O-(2) fluoroethyl-L-tyrosine (FET) PET; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: NAFLD
Interventions: Standard of care plus sugar-reduction education; Other
Lead sponsor: University of Southern California; Other
Eligibility: 12 Years to 18 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Migraine, Major Depressive Disorder
Interventions: Fremanezumab, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 17
States / cities: Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more

Conditions: Overweight, Cardiovascular Diseases
Interventions: High carbohydrate and low glycemic index (GI) diet, Low carbohydrate and low GI diet, High carbohydrate and high GI diet, Low carbohydrate and high GI diet; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 30 Years and older
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Obesity, Insulin Resistance
Interventions: Insulin, NG-monomethyl-L-arginine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Nephrotic Syndrome in Children
Interventions: Corticosteroids; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 1 Year to 18 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Sodium Excess, Racial Disparities, Blood Pressure, Cardiovascular Risk Factor
Interventions: Low Sodium Meal (140 mg sodium chloride), High Sodium Meal (2500 mg sodium chloride); Other
Lead sponsor: Indiana University; Other
Eligibility: 19 Years to 75 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Auburn, Alabama • Bloomington, Indiana

Conditions: Hysterectomy, Ovariectomy, Menopause, Testosterone Deficiency
Interventions: Testosterone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prediabetes
Interventions: Amylose, Amylopectin; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 35 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Metastatic Hormone Refractory Prostate Cancer
Interventions: Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer, Leukemia, Lymphoma, Gynecologic Cancer
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension, Hyperlipidemias
Interventions: Atorvastatin, placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Polycystic Ovary Syndrome, Obesity
Interventions: Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Insulin, Continuous glucose monitor (CGM); Drug · Device
Lead sponsor: Jagdeesh Ullal; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: docetaxel, ixabepilone, paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, paricalcitol; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hip Fracture
Interventions: PUSH, Protein, Nutrition; Behavioral · Dietary Supplement
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • Towson, Maryland

Conditions: Diabetes (DM)
Interventions: Glucagon, Saline (placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Calorie Restriction
Interventions: Not listed
Lead sponsor: Tufts University; Other
Eligibility: 33 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 3
States / cities: Baton Rouge, Louisiana • Boston, Massachusetts • St Louis, Missouri

Conditions: Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Interventions: Naproxen Sodium 550mg, Placebo, Extended Release Acetaminophen (650 mg); Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Hormone-Sensitive Breast Cancer, Breast Cancer
Interventions: Letrozole, Bevacizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: LowT, Resistance Training, Placebo, HighT; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years and older · Male only
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Acute Heart Failure
Interventions: Placebo, Nesiritide, Dopamine; Other · Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 7
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more

Search by objective public record fields.

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease

Healthy Eating Through Reduction Of Excess Sugar

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

Effect of Amount and Type of Dietary Carbohydrates on Risk for Cardiovascular Heart Disease and Diabetes

Plasma Triglyceride Extraction by The Muscle

Steroid Sensitive Nephrotic Syndrome in Children

Vascular Effects of Acute Sodium (VEAS) Study

TDSM- Testosterone Dose Response in Surgically Menopausal Women

Role of Slowly Digesible Starch on Diabetes Risk Factors

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Delayed Effects of Treatment in Cancer Survivors (DETECS)

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

PUSH Plus Protein Pilot for Hip Fracture Patients

Studies of Insulin and Glucagon Action in the Liver

The CALERIE™ Legacy Study

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

TEAM: Testosterone Supplementation and Exercise in Elderly Men

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study